GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Value Fund has reached the midpoint of 2025, recording a decline of -3.6% net of fees and expenses. The US dollar has experienced a substantial depreciation, negatively impacting performance by over 5.0% year-to-date (YTD). The fund’s robust beginning in Q1 was reversed in Q2 as markets shrugged off President Trump’s “Liberation Day” tariffs and adopted a full “risk on” stance. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.
In its second-quarter 2025 investor letter, GreensKeeper Asset Management highlighted stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and development, manufacture, and distribution of pharmaceutical products. The one-month return of Novo Nordisk A/S (NYSE:NVO) was -17.42%, and its shares lost 57.89% of their value over the last 52 weeks. On August 22, 2025, Novo Nordisk A/S (NYSE:NVO) stock closed at $56.98 per share, with a market capitalization of $246.974 billion.
Burke Wealth Management stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its second quarter 2025 investor letter:
“We made one new purchase in the quarter: Novo Nordisk A/S (NYSE:NVO), which we have owned previously. NVO, a Danish pharmaceutical company, is the world’s leading insulin maker. But today the company’s growth is driven by its GLP-1 franchise, which comprises Ozempic, Wegovy and Rybelsus. The stock has come under pressure following the uptake of competitor Eli Lilly’s (LLY) GLP-1 products Mounjaro and Zepbound. LLY will likely continue to gain share, but we believe the market for GLP-1s is large enough for both companies to continue increasing their revenues, and that the market is undervaluing NVO’s GLP-1 pipeline.”
Novo Nordisk A/S (NVO): “Canada’s A Backdoor,” Says Jim Cramer
An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.
Novo Nordisk A/S (NYSE:NVO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held Novo Nordisk A/S (NYSE:NVO) at the end of the second quarter, which was 60 in the previous quarter. While we acknowledge the potential of Novo Nordisk A/S (NYSE:NVO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Story Continues